E L Kuzmin

Novgorod Regional Clinical Hospital, Veliky Novgorod, Russia.

2 publications 2025 – 2025 ORCID
RussiaRegistriesIschemic StrokeFibrinolytic AgentsCerebral Hemorrhage

What does E L Kuzmin research?

E L Kuzmin studies how well Revelise, a drug commonly used to treat ischemic stroke, works for patients in everyday medical situations. Ischemic strokes happen when blood flow to the brain is blocked, leading to potential disabilities. Through large-scale studies, including thousands of patients, they examine how this medication can help improve outcomes, particularly for older adults and those with additional health challenges.

Key findings

  • In a study of 2,202 patients, nearly half (49.9%) experienced good outcomes upon discharge from treatment.
  • After 90 days, the rate of good outcomes increased to 66.4%, showing significant improvement over time.
  • The research indicates that Revelise effectively reduces disabilities caused by strokes, especially in older patients.

Frequently asked questions

Does Dr. Kuzmin study ischemic strokes?
Yes, Dr. Kuzmin specializes in researching treatments for ischemic strokes, particularly focusing on the medication Revelise.
What treatments has Dr. Kuzmin researched?
Dr. Kuzmin has researched the use of Revelise, an alteplase medication, in treating ischemic strokes and improving patient outcomes.
Is Dr. Kuzmin's work relevant to older stroke patients?
Yes, Dr. Kuzmin's research specifically includes older patients, showing effective outcomes in improving their recovery from strokes.

Publications in plain English

[Fortelyzin for acute ischaemic stroke treatment: an open, prospective, non-interventional, observational study FORPI registry].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Martynov MY, Gusev EI, Marskaya NA, Khasanova DR +92 more

Plain English
This study looked at how safe and effective the drug Fortelyzin is for treating patients with acute ischemic stroke (AIS). Researchers followed 17,636 patients across 329 centers between March 2021 and October 2024. They found that 61% of patients experienced good outcomes after 90 days, and only 2% had serious bleeding complications, which is similar to results from previous studies. This is important because it supports the use of Fortelyzin for patients suffering from strokes, potentially leading to better treatment options. Who this helps: Patients with acute ischemic stroke and their healthcare providers.

PubMed

[Thrombolytic Therapy for Ischemic Stroke with Revelise: Results of a Two-Year Follow-Up in the International PRIMA Study].

2025

Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova

Shamalov NA, Khasanova DR, Marchenko SV, Soldatov MA, Azarova AG +46 more

Plain English
This study looked at how well and safely Revelise (alteplase), a medication for treating ischemic stroke (IS), works in real-life situations. It involved 2,202 patients, mostly around 68 years old, and found that nearly half (49.9%) of them had good outcomes when discharged, rising to 66.4% after 90 days. The results showed that Revelise effectively reduces stroke-related disabilities, even in older patients and those with other health issues. Who this helps: This benefits patients who suffer from ischemic strokes and the doctors treating them.

PubMed

Publication data sourced from PubMed . Plain-English summaries generated by AI. Not medical advice.